ORAMORPH 6 mg/ml SOLUCION ORAL EN UNIDOSIS Spagna - spagnolo - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

oramorph 6 mg/ml solucion oral en unidosis

l. molteni & c. dei fratelli alitti societa di esercizio s.p.a. - morfina sulfato - soluciÓn oral - 30 mg - morfina sulfato 6 mg - morfina

Lorviqua Unione Europea - spagnolo - EMA (European Medicines Agency)

lorviqua

pfizer europe ma eeig - lorlatinib - carcinoma, pulmón no microcítico - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.

Cibinqo Unione Europea - spagnolo - EMA (European Medicines Agency)

cibinqo

pfizer europe ma eeig  - abrocitinib - dermatitis, atópica - otras preparaciones dermatológicas - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.

Movymia Unione Europea - spagnolo - EMA (European Medicines Agency)

movymia

stada arzneimittel ag - teriparatida - osteoporosis - homeostasis del calcio - movymia está indicado en adultos. tratamiento de la osteoporosis en mujeres posmenopáusicas y en hombres con mayor riesgo de fractura. en mujeres posmenopáusicas, se ha demostrado una reducción significativa en la incidencia de fracturas vertebrales y no vertebrales, pero no fracturas de cadera. el tratamiento de la osteoporosis asociada con sostenido sistémica de glucocorticoides terapia en las mujeres y los hombres en mayor riesgo de fractura.

Xalkori Unione Europea - spagnolo - EMA (European Medicines Agency)

xalkori

pfizer europe ma eeig - crizotinib - carcinoma, pulmón no microcítico - agentes antineoplásicos - xalkori as monotherapy is indicated for:the first‑line treatment of adults with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with previously treated anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with ros1‑positive advanced non‑small cell lung cancer (nsclc)the treatment of paediatric patients (age ≥6 to.

Vocabria Unione Europea - spagnolo - EMA (European Medicines Agency)

vocabria

viiv healthcare b.v. - cabotegavir sodium, cabotegravir - infecciones por vih - antivirales para uso sistémico - vocabria tablets are indicated in combination with rilpivirine tablets for the short-term treatment of human immunodeficiency virus type 1 (hiv-1) infection in adults who are virologically suppressed (hiv-1 rna.

Litfulo Unione Europea - spagnolo - EMA (European Medicines Agency)

litfulo

pfizer europe ma eeig - ritlecitinib tosilate - alopecia areata - inmunosupresores - litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.

Apretude Unione Europea - spagnolo - EMA (European Medicines Agency)

apretude

viiv healthcare b.v. - cabotegravir - infecciones por vih - antivirales para uso sistémico - apretude is indicated in combination with safer sex practices for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 infection in high-risk adults and adolescents, weighing at least 35 kg (see sections 4. 2, 4. 4 y 5.

Sixmo Unione Europea - spagnolo - EMA (European Medicines Agency)

sixmo

l. molteni & c. dei fratelli alitti società di esercizio s.p.a. - clorhidrato de buprenorfina - trastornos relacionados con los opioides - otras drogas del sistema nervioso - sixmo está indicado para el tratamiento de sustitución para la dependencia de opiáceos en clínicamente estable de los pacientes adultos que requieren no más de 8 mg/día de buprenorfina sublingual, dentro de un marco de médicos, sociales y psicológicos de tratamiento.